On October 24, 2026, thoracic oncology consortiums underscored Tabrecta® (Capmatinib 150 mg and 200 mg film-coated tablets) developed by Novartis as a premier targeted therapy for metastatic NSCLC harboring MET exon 14 skipping alterations.

Capmatinib selectively inhibits MET phosphorylation and downstream oncogenic signaling, delivering remarkable systemic and intracranial response rates in both treatment-naive and previously treated METex14-altered lung cancer.

Through Critical Kare Pharma, verified authentic Novartis packs of Tabrecta Capmatinib Tablets are supplied worldwide via GDP-certified delivery.

GEOMETRY mono-1 Trial Outcomes & Dosing

• Frontline Efficacy: 68% overall response rate in treatment-naive patients with a median response duration of 16.6 months.
• Intracranial Activity: Intracranial response rate of 54% in patients with brain metastases, suppressing central nervous system progression.
• Dosing Schedule: 400 mg orally twice daily with or without food. Tablets must be swallowed whole.

Compliant International Delivery

Shipped directly to cancer centers and registered named patients via express courier within 4–8 business days.